Bio-Rad now sees non-GAAP revenue for FY down 1% to up 1.5%

Bio-Rad (BIO) is updating its financial outlook for the full year 2025. The company currently expects non-GAAP, currency-neutral revenue to range from approximately a 1.0 percent decline to 1.5 percent growth versus its prior revenue growth estimate of approximately 1.5 to 3.5 percent, and an estimated non-GAAP operating margin of approximately 10.0 to 12.0 percent compared to its prior expectation of approximately 13.0 to 13.5 percent.